Safe Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 21-06-2024
- Paid Up Capital ₹ 0.73 M
as on 21-06-2024
- Company Age 42 Year, 9 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 21.69 Cr
as on 21-06-2024
- Revenue %
(FY 2020)
- Ebitda
- Net Worth
- Total Assets %
(FY 2020)
About Safe Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.73 M.
The company currently has active open charges totaling ₹21.69 Cr.
Kanigiri Gade and Sanagala Reddy serve as directors at the Company.
- CIN/LLPIN
U24239AP1982PTC003419
- Company No.
003419
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Mar 1982
- Date of AGM
26 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Guntur, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Safe Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kanigiri Gade  | Director | 13-May-2020 | Current |
| Sanagala Reddy | Director | 13-May-2020 | Current |
Financial Performance of Safe Pharmaceuticals.
Safe Pharmaceuticals Pvt Ltd, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Safe Pharmaceuticals?
In 2020, Safe Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Pranaya Pharmaceuticals Private LimitedActive 4 years 9 monthsKanigiri Gade and Sanagala Reddy are mutual person
Pranaya Parenterals Private LimitedActive 4 years 5 monthsKanigiri Gade and Sanagala Reddy are mutual person
- Intertech Labs Private LimitedActive 5 years 8 months
Kanigiri Gade and Sanagala Reddy are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Bank Creation Date: 26 Feb 2019 | ₹18.75 Cr | Open |
Indian Bank Creation Date: 16 Apr 2010 | ₹2.80 Cr | Open |
The Vysya Bank Creation Date: 20 Mar 1985 | ₹0.50 M | Open |
How Many Employees Work at Safe Pharmaceuticals?
Unlock and access historical data on people associated with Safe Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Safe Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Safe Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
